Autres langues Cassava Sciences, Inc.

Actions

SAVA

US14817C1071

Temps réel estimé Cboe BZX Autres places de cotation 17:59:40 01/05/2024			Varia. 5j.	Varia. 1 janv.
22,09 ^USD	-0,27%		+6,61%	-1,78%

25/03	Cassava Sciences annonce l'achèvement de l'évaluation intermédiaire de la sécurité du simufilam, son médicament candidat contre la maladie d'Alzheimer	MT
25/03	Cassava Sciences, Inc. annonce l'achèvement d'une évaluation intermédiaire de la sécurité du simufilam oral dans le cadre des essais cliniques de phase 3 en cours	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ	15:10
North American Morning Briefing : Investors Brace -2-	29/04
Cassava Sciences : Corporate Presentation – Second Quarter 2024	24/04
Cassava Sciences, Inc. - Redemption Date Announced for Warrants	16/04
Redemption Date Announced for Warrants	15/04
Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava	29/03
ROSEN, A LONGSTANDING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important April 2 Deadline in Securities Class Action - SAVA	27/03
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA	27/03
Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam	25/03
Cassava Sciences : Corporate Presentation – First Quarter 2024	25/03
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials	25/03
Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials	25/03
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava	21/03
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA	20/03
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA	19/03
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA	19/03
ROSEN, A TOP RANKED LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA	17/03
ROSEN, A LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA	15/03
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava	13/03
Thinking about buying stock in Lexicon Pharmaceuticals, Cassava Sciences, Clearside Biomedical, Lantern Pharma, or ATAI Life Sciences?	13/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Cassava Sciences, Inc.

Actions

SAVA

US14817C1071

Autres langues

Filtres